- Home
- LNKB vs ADCT Comparison
LNKB vs ADCT Comparison
Compare LNKB & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LNKB | ADCT |
|---|---|---|
| Founded | 2018 | 2011 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 261.4M | 496.7M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | LNKB | ADCT |
|---|---|---|
| Price | $8.25 | $4.28 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $9.00 | $7.60 |
| AVG Volume (30 Days) | 149.5K | ★ 1.6M |
| Earning Date | 01-26-2026 | 11-10-2025 |
| Dividend Yield | ★ 3.64% | N/A |
| EPS Growth | ★ 512.12 | N/A |
| EPS | ★ 1.03 | N/A |
| Revenue | ★ $122,594,000.00 | $75,209,000.00 |
| Revenue This Year | $18.38 | $10.36 |
| Revenue Next Year | $0.35 | $3.87 |
| P/E Ratio | $8.03 | ★ N/A |
| Revenue Growth | ★ 42.32 | 6.35 |
| 52 Week Low | $6.09 | $1.05 |
| 52 Week High | $8.25 | $4.80 |
Technical Indicators
Market Signals| Indicator | LNKB | ADCT |
|---|---|---|
| Relative Strength Index (RSI) | 72.17 | 55.06 |
| Support Level | $7.59 | $3.15 |
| Resistance Level | $8.15 | $4.62 |
| Average True Range (ATR) | 0.24 | 0.40 |
| MACD | 0.05 | 0.01 |
| Stochastic Oscillator | 98.96 | 77.98 |
Price Performance
Historical ComparisonAbout LNKB LINKBANCORP Inc.
Linkbancorp Inc operates in the banking industry. It provides banking services for individuals and businesses such as commercial lending, non-profit banking, treasury management, deposits and loans. Company portfolio segments includes: Agriculture and farmland, Construction, Commercial & industrial, Commercial real estate, Residential real estate, Municipal, customers and Other loans.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).